TMC647055 + TMC435

TMC647055 + TMC435 is an investigational **oral combination therapy** targeting chronic genotype 1 hepatitis C virus (HCV) infection. TMC647055 is a **potent non-nucleoside inhibitor of the HCV NS5B RNA-dependent RNA polymerase** with a macrocyclic indole structure and high genotypic coverage, while TMC435 (also known as **simeprevir**) is a **NS3/4A protease inhibitor**, blocking proteolytic processing of viral polyproteins required for HCV replication[1][5][7]. The combination is intended to suppress HCV replication and prevent resistance by simultaneously inhibiting complementary targets in the viral life cycle[1][5][7]. The regimen is being explored with or without the pharmacokinetic enhancer ritonavir and with or without ribavirin, sometimes with other direct acting antivirals[2][3][5][6].

Other names

Simeprevir + TMC647055